ECOG-ACRIN Office of Communications
Satellite meetings at the November RSNA annual meeting for interested investigators
Philadelphia, October 25, 2016 —The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first large-scale breast cancer screening trial in nearly 25 years, is approved for funding by the National Cancer Institute (NCI). The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), leading the trial, is now recruiting medical facilities as it prepares to open the trial in mid-2017.
TMIST will enroll 165,000 asymptomatic women in the US and Canada, between the ages of 45 and 74, to compare the incidence of advanced cancers in those screened for four years with digital breast tomosynthesis vs. standard digital mammography. The study aims to provide a modern basis for the continued use of mammography for breast cancer screening.
Interested medical imaging providers can attend one of two TMIST informational sessions while at the upcoming Radiological Society of North America (RSNA) annual meeting in Chicago:
No pre-registration is required to attend.
To participate in TMIST, a medical facility must be (1) located in the US, (2) able to provide both imaging methods in the same location, and (3) a member of a research group in the NCI National Clinical Trials Network (NCTN), either directly or through the NCI Community Oncology Research Program (NCORP). TMIST will require nearly 100 sites, estimating that each will enroll about four to five women per day to reach the accrual goal in about three years.
Available for interviews are the following spokespersons for TMIST: lead investigator Etta D. Pisano, MD at Beth Israel Deaconess Medical Center and Harvard Medical School; lead statistician Constantine A. Gatsonis, PhD at the ECOG-ACRIN Biostatistics and Data Management Center located at the Brown University Center for Statistical Sciences; and ECOG-ACRIN group co-chair Mitchell D. Schnall, MD, PhD at the University of Pennsylvania.
TMIST image acquisition, storage, and sharing will be carried out at the ACR Center for Research and Innovation. Dr. Gatsonis will lead the TMIST statistical analysis.
The NTCN research groups are the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG.
Imaging providers can submit email inquiries at www.ecog-acrin.org/contact-us to check on their NCTN status or ask questions about the trial.
About the ECOG-ACRIN Cancer Research Group
The ECOG-ACRIN Cancer Research Group is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. ECOG-ACRIN comprises nearly 1100 member institutions in the United States and around the world. Approximately 12,000 physicians, translational scientists, and associated research professionals from the member institutions are involved in Group research, which is organized into three scientific programs: Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences. ECOG-ACRIN is supported primarily through National Cancer Institute research grant funding, but also receives funding from private sector organizations through philanthropy and collaborations. It is headquartered in Philadelphia, Pa. For more information, visit www.ecog-acrin.org or call 215.789.3631.